What a night! 🥂Our team had a great time at the #Endpoints11 event where we were able to congratulate our fellow awardees, hear from biotech luminary, Bob Langer, and celebrate with the talented Endpoints News team. Thanks again for the recognition! tinyurl.com/2rjbvpaa

Four days until the Foundation Fighting Blindness 17th Annual Boston #VisionWalk! 🦮 Register here to join us this Saturday, October 5, and be sure to stop by the Ascidian booth to say hello: bit.ly/4fKPYy2

#TeamAscidian had a whale of a time at last night’s #Fierce15 Award Ceremony! 🏆🎉 We’re on a roll – and more motivated than ever to bring #RNAExonEditing to patients. Thank you again, FierceBiotech, for the recognition.

#TeamAscidian is thrilled to be Alliance for Regenerative Medicine (ARM)'s #CGMesa24 in Arizona.🌵Join us Wednesday morning as our Chief Financial & Business Officer, Daniel Rosan, takes the podium to share the latest on all things #RNAExonEditing. Don't miss it—see you there!

Congratulations to Ascidian President and CEO, Michael Ehlers, MD, PhD, for being named to the #PharmaVoice100, recognizing individuals who are a driving force in the industry. We’re proud to have Mike on #TeamAscidian.👏tinyurl.com/5n6w2chj

For #WorldSightDay, we’re celebrating Lucia & Sarafina, the “Stargardt Sisters,” who share a special bond. Thanks to their mom, Sarah, for speaking with us & reinforcing why we do what we do. Learn about their story from Foundation Fighting Blindness: tinyurl.com/37xtca3a #ShareYourVision

Thank you, Bradford Manning, for an incredible master class on #StargardtDisease. We're grateful to be part of it. Don't miss out –#BlindnessAwarenessMonth is the perfect time to explore this important curriculum: bit.ly/3yB9trX #ShareYourVoice

Curious about the cutting-edge field of RNA editing? Check out this article from BioPharma Dive to explore its evolution, latest breakthroughs, and how Ascidian's #RNAExonEditors could expand the possibilities of RNA medicines. 👉tinyurl.com/t2uub2vr

#RNAEditing is receiving global attention. In this @Nikkei piece, we explain how we were "able to reach clinical trials in a shorter period of time & with less investment than any other preceding gene editing technology” for our lead program👉 tinyurl.com/2bncrdkx

On Nov 2, we’ll be The Carroll Center for the Blind for the Blind diving into 1⃣ #RNAExonEditing 2⃣ ACDN-01, our lead program targeting #StargartDisease 3⃣ The #STELLARClinicalTrial Check out the event details here: tinyurl.com/mrx7ux6u

#TeamAscidian was thrilled to present The Carroll Center for the Blind for the Blind earlier this month about #RNAExonEdting, ACDN-01 – our lead program in #StargardtDisease, and the #STELLARClinicalTrial. Couldn’t be there?  Watch the recording to learn more👇youtu.be/sGKsci5ZY8s?si…

Always a pleasure to talk to our friends Foundation Fighting Blindness!🎙️Check out this Eye on the Cure podcast episode with Robert Bell & host Ben Shaberman diving into the #STELLARClinicalTrial for #StargardtDisease & the promise of #RNAExonEditing👉tinyurl.com/2b8shpks

👀👀 Great way to close out the year? Being named a 2024 biopharma winner by Endpoints News! 🏆 Winner: RNA editing Get the scoop 👉 endpts.com/endpoints-winn… #RNAExonEditing

🎉 As 2024 comes to a close, we’re filled with gratitude for everyone on #TeamAscidian and the hard work and dedication that made this a milestone year. Wishing all of our team, and all of you, a restful and joyful holiday break, and all the best in 2025! ❄️✨ #HappyHolidays

#ICYMI: Holiday drive-time is perfect for catching the latest Foundation Fighting Blindness podcast featuring Bob Bell! 🚗 Hear about #RNAExonEditing, the #STELLARClinicalTrial for #StargardtDisease, & more. Happy listening & #HappyHolidays ⛄️from #TeamAscidian.  🎧➡️bit.ly/4g18Loq

Catch ASGCT’s latest Molecular Therapy Podcast with Paloma Giangrande and Ascidian's CEO & CSO as they explore #RNAExonEditing and our recent article in Molecular Therapy Family of Journals. Heading to #JPM25? Listen on your way!🎧Apple: bit.ly/4gL2KMM Spotify: bit.ly/4j7Gyhr

We’re diving into the new year & taking off for #JPM2025 ✈️. If you’re doing the same, head over to Goodwin + KPMG 's 6th Annual Symposium where our own Dan Rosan will be part of their expert panel on 'Shaping the Future of Life Sciences Partnerships'. Hope to see you there!

As #JPM2025 wraps, a highlight was our own Dan Rosan sharing insights @Goodwinlaw + KPMG. "Timing & focus are essential for small companies. We need to approach collaborations with a clear path toward delivering transformative therapies that solve real-world clinical problems."

RNA editing’s clinical momentum is undeniable. With a differentiated large scale RNA exon editing approach, Ascidian is advancing RNA editing in Stargardt disease—and beyond. We’re just getting started. Read more: bit.ly/4hbVZmV

More scientists, biotech journalists, and industry leaders are joining Bluesky, and Ascidian is excited to join them. We'll no longer be on X, but you can follow us on Bluesky at @ascidiantx.bsky.social to stay updated on our science and milestones.